This Week’s CGT News: Radiopharmaceutical Boosts CAR T - Report - MDSpire
Advertisement
This Week’s CGT News: Radiopharmaceutical Boosts CAR T
A targeted radiopharmaceutical improves CAR T activity in neuroblastoma models, engineered Tregs suppress allergic asthma, and new gene therapy platforms target MMA and the brain
Clinical Report: Radiopharmaceutical Boosts CAR T in Neuroblastoma Models
Overview
A targeted radiopharmaceutical has been shown to enhance CAR T cell therapy efficacy in preclinical neuroblastoma models. The combination therapy resulted in greater tumor regression compared to either treatment alone.
Background
The integration of radiopharmaceuticals with CAR T cell therapy represents a novel approach to enhance the effectiveness of immunotherapy in treating high-risk cancers. Neuroblastoma is a challenging pediatric malignancy that often requires innovative strategies.
Data Highlights
No numerical data provided in the source material.
Key Findings
A targeted radiopharmaceutical, [67Cu]Cu-LLP2A, was combined with CAR T cells to improve treatment outcomes in neuroblastoma.
The combination therapy resulted in greater tumor regression than either CAR T cells or the radiopharmaceutical alone.
In radiation-sensitive tumors, the radiopharmaceutical directly damaged cancer cells and primed them for CAR T attack.
In radiation-resistant tumors, the treatment reshaped the tumor microenvironment, reducing suppressive macrophages.
This approach supports the development of cytotoxic CAR T cell niches within the tumor microenvironment.
Clinical Implications
Further clinical investigation is warranted to evaluate the safety and effectiveness of this combination in human subjects.
Conclusion
The study indicates a potential avenue for improving CAR T cell therapy through the use of targeted radiopharmaceuticals in neuroblastoma treatment.
